Dual Antiplatelet Therapy with Clopidogrel and Aspirin

Appropriate Indications for Combination Therapy

The American Heart Association recommends dual antiplatelet therapy with clopidogrel and aspirin for patients with acute coronary syndrome (ACS) and recent coronary stent placement 1, 2
Patients with bare-metal stents should receive at least 1 month of dual therapy, while those with drug-eluting stents should receive at least 12 months of dual therapy, as recommended by the American College of Cardiology 3, 4
Combination therapy with clopidogrel 75mg and aspirin 75-100mg is recommended for patients with unstable angina or non-Q-wave MI, according to the American Heart Association 5

The American Stroke Association does not recommend the combination of clopidogrel and aspirin for secondary prevention of stroke or TIA in patients without acute coronary disease or recent coronary stent 1, 2
Patients with recent ischemic stroke treated with both medications showed insignificant reduction in major cardiovascular events but experienced more life-threatening hemorrhages, as reported by the American Heart Association 4

Consider proton pump inhibitor (PPI) prophylaxis in patients requiring dual antiplatelet therapy to reduce gastrointestinal bleeding risk, as suggested by the American College of Cardiology 6

For stroke/TIA prevention, the American Stroke Association recommends using aspirin plus extended-release dipyridamole as first choice, or clopidogrel alone as an alternative 2
For aspirin intolerance, the American Heart Association recommends clopidogrel alone for those who cannot tolerate aspirin 1, 2
For atrial fibrillation, anticoagulation therapy is preferred over antiplatelet therapy for stroke prevention, according to the American Heart Association 2

The American College of Cardiology recommends typically 12 months of dual therapy for ACS without stent placement 4
For bare-metal stents, at least 1 month of dual therapy is recommended, while for drug-eluting stents, at least 12 months of dual therapy is recommended, as suggested by the American College of Cardiology 4

Certain PPIs (particularly omeprazole) may reduce clopidogrel's effectiveness, as reported by the American College of Cardiology 3, 4
History of bleeding, older age, renal insufficiency, and concomitant use of anticoagulants or NSAIDs increase bleeding risk, according to the American Heart Association 3

The European Society of Cardiology recommends dual antiplatelet therapy (DAPT) with aspirin 75-100 mg daily plus clopidogrel 75 mg daily for at least 12 months after any acute coronary syndrome, regardless of whether the patient underwent stenting 7, 8
For patients who underwent percutaneous coronary intervention (PCI) with stenting, DAPT is recommended for up to 6 months as the default strategy 7, 8
Extended DAPT beyond 12 months may be considered in patients at high ischemic risk who are not at high bleeding risk, according to the European Heart Journal 8

In patients at high bleeding risk but not at high ischemic risk, discontinue DAPT after 1-3 months and continue single antiplatelet therapy, as recommended by the European Heart Journal 8
Proton pump inhibitor prophylaxis is recommended for all patients on DAPT to reduce gastrointestinal bleeding risk, with pantoprazole or esomeprazole preferred over omeprazole 8

In patients with atrial fibrillation or other indications for oral anticoagulation who undergo PCI, aspirin should be discontinued early (within 1 week) after uncomplicated stenting, and dual therapy with oral anticoagulant plus clopidogrel should be continued for 6-12 months depending on ischemic risk 7, 9, 8
Triple therapy (aspirin + clopidogrel + anticoagulant) should be limited to ≤1 month only when stent thrombosis risk outweighs bleeding risk, according to the European Heart Journal 10, 9, 8